Investor Relations

Exploring New Compounds to Meet the Challenge of Cancer Treatment Resistance

OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer.  We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.

View Corporate Fact Sheet

Currently, we have two candidates in clinical development across multiple oncology therapeutic areas and an additional candidate in pre-clinical development:

Custirsen (Phase 3 in prostate and lung cancers)

OncoGenex’s lead compound, custirsen, is an experimental drug designed to block the production of the protein clusterin, which may play a fundamental role in cancer cell survival and treatment resistance. Learn More.

OGX-427 (Phase 2 in bladder, lung, pancreatic and prostate cancers)

OGX-427 is an investigational drug designed to inhibit the production of heat shock protein (Hsp27), a protein that is elevated in many cancers and that has been shown to promote cancer cell growth and tumor metastasis. Learn More.

Role of Hsp27 and OGX-427 Mechanism of Action Video

OGX-225 (Preclinical)

View Product Pipeline

Stock quote (NASDAQ: OGXI)
Price: 10.66    Change: + 0.49    Volume 63,500
3:21 PM ET on May 23, 2013
Delayed at least 20 minutes. Provided by eSignal.